DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» T790M
T790M
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
The Impact of EGFR T790M Mutations and BIM Mrna Expression On
Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
NSCLC): Initial Findings from the SUMMIT Basket Trial
Puma Biotechnology
Integrative Profiling of T790M Negative EGFR Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
Epidermal Growth Factor Receptor T790M Mutation As a Prognostic
Irreversible Inhibitors of the EGF Receptor May Circumvent Acquired Resistance to Gefitinib
Dual Targeting of the Epidermal Growth Factor Receptor Using
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations, Biomol
Amplification of EGFR T790M Causes Resistance to An
Osimertinib in EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer Ferdinandos Skoulidis and Vassiliki A
Epidermal Growth Factor Receptor T790M Mutation-Positive Metastatic Non-Small-Cell Lung Cancer: Focus on Osimertinib (AZD9291)
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
Raman Micro-Spectroscopy Monitors Acquired Resistance to Targeted
The Ratio of T790M to EGFR-Activating Mutation Predicts Response of Osimertinib in 1St Or 2Nd Generation EGFR-TKI-Refractory
Clinical Validation of a Highly Sensitive Assay to Detect EGFR Mutations in Plasma Cell-Free DNA from Patients with Advanced Lung Adenocarcinoma
Top View
Non-Small Cell Lung Cancer
AZD9291 in Epidermal Growth Factor Receptor Inhibitor—Resistant Non-Small-Cell Lung Cancer
Patient with Primary T790M Mutation in Lung Adenocarcinoma Treated
Generation EGFR TKI for the Treatment of EGFR+/T790M/C797S Resistant
Lung Cancer and the EGFR T790M Mutation
EGFR T790M Mutation: a Double Role in Lung Cancer Cell Survival?
Low T790M Relative Allele Frequency Indicates Concurrent Resistance Mechanisms and Poor Responsiveness to Osimertinib
Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer
EGFR C797S, EGFR T790M and EGFR Sensitizing Mutations in Non-Small Cell Lung Cancer Revealed by Six-Color Crystal Digital PCR
The T790M ''Gatekeeper'' Mutation in EGFR Mediates Resistance to Low Concentrations of an Irreversible EGFR Inhibitor
Can a T790M Mutation-Positive Cancer Change Its Spots After Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitor Therapy?
Activating and Resistance Mutations of EGFR in Non-Small-Cell Lung Cancer: Role in Clinical Response to EGFR Tyrosine Kinase Inhibitors
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI
EGFR T790M Mutation As a Novel Target for Immunotherapy Against
Olmutinib in T790M‐Positive Non–Small Cell Lung Cancer After Failure
The Efficacy and Safety of Osimertinib in Advanced Non-Small Cell Lung Cancer Patients with Thr790met Resistance Mutations: a Systematic Review and Meta-Analysis
Characterization of EGFR T790M, L792F, and C797S Mutations As
Impact on Prognosis of Rebiopsy in Advanced Non-Small Cell Lung
Osimertinib in Advanced EGFR T790M-Positive Non-Small-Cell Lung Cancer: the Clinical Impact of AURA3
The T790M Resistance Mutation in EGFR Is Only Found in Cfdna From
Frequency of EGFR T790M Mutation and Multimutational Profiles Of
Efficacy of Second-Line Tyrosine Kinase Inhibitors in the Treatment Of
Conformational Insight on WT- and Mutated-EGFR Receptor Activation
HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2- Positive and HER2-Mutated Breast Cancer
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials
Novel Drug Development of the Next-Generation T790M Mutant Specific Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Osimertinib Benefit in EGFR-Mutant NSCLC Patients with T790M-Mutation Detected by Circulating Tumour DNA
Sequential Use of EGFR-Tyrosine Kinase Inhibitors Based Upon EGFR Mutation Evolution Achieves Long-Term Control in a Non-Small Cell Lung Cancer Patient: a Case Report
A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients
Effective Treatment of Pulmonary Adenocarcinoma Harboring Triple
Acquired Resistance of EGFR-Mutant Lung Cancer to A
Deciphering Mechanisms of Acquired T790M Mutation After EGFR
EGFR Testing for Non-Small Cell Lung Cancer TKI Response
EGFR T790M Detection in Circulating Tumor DNA from Non-Small Cell
The Epidermal Growth Factor Receptor (EGFR / HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer
Clinical Significance of Repeat Rebiopsy in Detecting the EGFR T790M Secondary Mutation in Patients with Non-Small Cell Lung Cancer
Structural Basis for the Altered Drug Sensitivities of Non-Small Cell Lung Cancer-Associated Mutants of Human Epidermal Growth Factor Receptor
Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR
Mutational Monitoring of EGFR T790M in Cfdna for Clinical Outcome Prediction in EGFR- Mutant Lung Adenocarcinoma
Assessment of EGFR Gene Mutations in Circulating Free DNA in Monitoring of Response to EGFR Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma